Identification of promoters bound by c-Jun/ATF2 during rapid large-scale gene activation following genotoxic stress

Molecular Cell

Volumn 16, Issue 4, 2004, Pages 521-535

  Hayakawa, Jun ^a   Mittal, Shalu ^a   Wang, Yipeng ^a   Korkmaz, Kemal S ^a   Adamson, Eileen ^b   English, Christopher ^a,c   Omichi, Masahide ^d   McClelland, Michael ^a,c   Mercola, Dan ^a,c  

^a SIDNEY KIMMEL CANCER CENTER   (United States)

^b BURNHAM INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CISPLATIN; DNA; PROTEIN C JUN; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE INHIBITOR;

ARTICLE; CHROMATIN; CONTROLLED STUDY; DNA REPAIR; GENE ACTIVATION; GENE EXPRESSION; GENE IDENTIFICATION; GENOTOXICITY; HUMAN; HUMAN CELL; HYBRIDIZATION; IMMUNOPRECIPITATION; MOLECULAR MODEL; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; STRESS; UNINDEXED SEQUENCE;

ACTIVATING TRANSCRIPTION FACTOR 2; ANTHRACENES; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; CISPLATIN; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DNA REPAIR; DNA-BINDING PROTEINS; ENZYME INHIBITORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHORYLATION; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-JUN; RNA, SMALL INTERFERING; TIME FACTORS; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 8844285956     PISSN: 10972765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molcel.2004.10.024     Document Type: Article

References (74)

1. Adler V., Pincus M.R., Brandt-Rauf P.W., Ronai Z. Complexes of p21RAS with JUN N-terminal kinase and JUN proteins. Proc. Natl. Acad. Sci. USA. 92:1995;10585-10589
2. Angel P., Allegretto E.A., Okino S.T., Hattori K., Boyle W.J., Hunter T., Karin M. Oncogene jun encodes a sequence-specific trans-activator similar to AP- 1. Nature. 332:1988;166-171
3. Bennett B.L., Sasaki D.T., Murray B.W., O'Leary E.C., Sakata S.T., Xu W., Leisten J.C., Motiwala A., Pierce S., Satoh Y., et al. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. USA. 98:2001;13681-13686
4. Bogoyevitch M.A., Boehm I., Oakley A., Ketterman A.J., Barr R.K. Targeting the JNK MAPK cascade for inhibition. basic science and therapeutic potential Biochim. Biophys. Acta. 1697:2004;89-101
5. Brivanlou A.H., Darnell J.E. Jr. Signal transduction and the control of gene expression. Science. 295:2002;813-818
6. Cavigelli M., Dolfi F., Claret F.X., Karin M. Induction of c-fos expression through JNK-mediated TCF/Elk-1 phosphorylation. EMBO J. 14:1995;5957-5964
7. Chen N., She Q.B., Bode A.M., Dong Z. Differential gene expression profiles of Jnk1- and Jnk2-deficient murine fibroblast cells. Cancer Res. 62:2002;1300-1304
8. Dabholkar M., Vionnet J., Bostick-Bruton F., Yu J.J., Reed E. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J. Clin. Invest. 94:1994;703-708
9. Dalgaard P. Statistics and Computing. Introductory Statistics with R:2002;Springer-Verlag, New York
10. Davis P.L., Shaiu W.L., Scott G.L., Iglehart J.D., Hsieh T.S., Marks J.R. Complex response of breast epithelial cell lines to topoisomerase inhibitors. Anticancer Res. 18:1998;2919-2932
11. de Belle I., Mercola D., Adamson E.D. Method for cloning in vivo targets of the Egr-1 transcription factor. Biotechniques. 29:2000;162-169
12. Dempke W., Voigt W., Grothey A., Hill B.T., Schmoll H.J. Cisplatin resistance and oncogenes-a review. Anticancer Drugs. 11:2000;225-236
13. Derijard B., Hibi M., Wu I.H., Barrett T., Su B., Deng T., Karin M., Davis R.J. JNK1. a protein kinase stimulated by uv light and ha-ras that binds and phosphorylates the c-jun activation domain Cell. 76:1994;1025-1037
14. Devary Y., Gottlieb R.A., Lau L.F., Karin M. Rapid and preferential activation of the c-jun gene during the mammalian UV response. Mol. Cell. Biol. 11:1991;2804-2811
15. Duckett D.R., Drummond J.T., Murchie A.I., Reardon J.T., Sancar A., Lilley D.M., Modrich P. Human MutSalpha recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct. Proc. Natl. Acad. Sci. USA. 93:1996;6443-6447
16. Eastman A. Glutathione-mediated activation of anticancer platinum(IV) complexes. Biochem. Pharmacol. 36:1987;4177-4178
17. el-Deiry W.S. Regulation of p53 downstream genes. Semin. Cancer Biol. 8:1998;345-357
18. Elstner E., Linker-Israeli M., Said J., Umiel T., de Vos S., Shintaku I.P., Heber D., Binderup L., Uskokovic M., Koeffler H.P. 20-epi-vitamin D3 analogues. a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines Cancer Res. 55:1995;2822-2830
19. Ginestier C., Charafe-Jauffret E., Bertucci F., Eisinger F., Geneix J., Bechlian D., Conte N., Adelaide J., Toiron Y., Nguyen C., et al. Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. Am. J. Pathol. 161:2002;1223-1233
20. Gong P., Stewart D., Hu B., Vinson C., Alam J. Multiple basic-leucine zipper proteins regulate induction of the mouse heme oxygenase-1 gene by arsenite. Arch. Biochem. Biophys. 405:2002;265-274
21. Greenbaum D., Jansen R., Gerstein M. Analysis of mRNA expression and protein abundance data. an approach for the comparison of the enrichment of features in the cellular population of proteins and transcripts Bioinformatics. 18:2002;585-596
22. Hagmeyer B.M., Angel P., van Dam H. Modulation of AP-1/ATF transcription factor activity by the adenovirus-E1A oncogene products. Bioessays. 17:1995;621-629
23. Hayakawa J., Depatie C., Ohmichi M., Mercola D. The activation of c-Jun NH2-terminal kinase (JNK) by DNA-damaging agents serves to promote drug resistance via activating transcription factor 2 (ATF2)-dependent enhanced DNA repair. J. Biol. Chem. 278:2003;20582-20592
24. Heinemeyer T., Wingender E., Reuter I., Hermjakob H., Kel A.E., Kel O.V., Ignatieva E.V., Ananko E.A., Podkolodnaya O.A., Kolpakov F.A., et al. Databases on transcriptional regulation. TRANSFAC, TRRD and COMPEL Nucleic Acids Res. 26:1998;362-367
25. Hunter T. "The role of tyrosine phosphorylation in cell growth and disease." In The Harvey Lectures Series 94, 1998-1999. 2000;John Wiley and Sons, New York. pp. 81-120.
26. Jin W., Riley R.M., Wolfinger R.D., White K.P., Passador-Gurgel G., Gibson G. The contributions of sex, genotype and age to transcriptional variance in Drosophila melanogaster. Nat. Genet. 29:2001;389-395
27. Kalodimos C.G., Biris N., Bonvin A.M., Levandoski M.M., Guennuegues M., Boelens R., Kaptein R. Structure and flexibility adaptation in nonspecific and specific protein-DNA complexes. Science. 305:2004;386-389
28. Kerppola T.K., Luk D., Curran T. Fos is a preferential target of glucocorticoid receptor inhibition of AP-1 activity in vitro. Mol. Cell. Biol. 13:1993;3782-3791
29. Kharbanda S., Ren R., Pandey P., Shafman T.D., Feller S.M., Weichselbaum R.R., Kufe D.W. Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents. Nature. 376:1995;785-788
30. Kim S.J., Angel P., Lafyatis R., Hattori K., Kim K.Y., Sporn M.B., Karin M., Roberts A.B. Autoinduction of transforming growth factor beta 1 is mediated by the AP-1 complex. Mol. Cell. Biol. 10:1990;1492-1497. a
31. Kool J., Hamdi M., Cornelissen-Steijger P., van der Eb A.J., Terleth C., van Dam H. Induction of ATF3 by ionizing radiation is mediated via a signaling pathway that includes ATM, Nibrin1, stress-induced MAPkinases and ATF-2. Oncogene. 22:2003;4235-4242
32. Lee J.H., Jang S.I., Yang J.M., Markova N.G., Steinert P.M. The proximal promoter of the human transglutaminase 3 gene. Stratified squamous epithelial-specific expression in cultured cells is mediated by binding of Sp1 and ets transcription factors to a proximal promoter element. J. Biol. Chem. 271:1996;4561-4568
33. Lee H.Y., Sueoka N., Hong W.K., Mangelsdorf D.J., Claret F.X., Kurie J.M. All-trans-retinoic acid inhibits Jun N-terminal kinase by increasing dual-specificity phosphatase activity. Mol. Cell. Biol. 19:1999;1973-1980
34. Li J., Smithgall T.E. Fibroblast transformation by Fps/Fes tyrosine kinases requires Ras, Rac, and Cdc42 and induces extracellular signal-regulated and c-Jun N- terminal kinase activation. J. Biol. Chem. 273:1998;13828-13834
35. Lonnstedt I., Speed T. Replicated Microarray Data. Statistica Sinica. 12:2002;31-46
36. Manning A.M., Davis R.J. Targeting JNK for therapeutic benefit. from junk to gold? Nat. Rev. Drug Discov. 2:2003;554-565
37. Mer G., Bochkarev A., Gupta R., Bochkareva E., Frappier L., Ingles C.J., Edwards A.M., Chazin W.J. Structural basis for the recognition of DNA repair proteins UNG2, XPA, and RAD52 by replication factor RPA. Cell. 103:2000;449-456
38. Mettouchi A., Cabon F., Montreau N., Dejong V., Vernier P., Gherzi R., Mercier G., Binetruy B. The c-Jun-induced transformation process involves complex regulation of tenascin-C expression. Mol. Cell. Biol. 17:1997;3202-3209
39. Minden A., Lin A., Smeal T., Derijard B., Cobb M., Davis R., Karin M. c-Jun N-terminal phosphorylation correlates with activation of the JNK subgroup but not the ERK subgroup of mitogen-activated protein kinases. Mol. Cell. Biol. 14:1994;6683-6688
40. Nehme A., Baskaran R., Aebi S., Fink D., Nebel S., Cenni B., Wang J.Y., Howell S.B., Christen R.D. Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin. Cancer Res. 57:1997;3253-3257
41. Niedner H., Christen R., Lin X., Kondo A., Howell S.B. Identification of genes that mediate sensitivity to cisplatin. Mol. Pharmacol. 60:2001;1153-1160
42. Offer H., Erez N., Zurer I., Tang X., Milyavsky M., Goldfinger N., Rotter V. The onset of p53-dependent DNA repair or apoptosis is determined by the level of accumulated damaged DNA. Carcinogenesis. 23:2002;1025-1032
43. Onoa G.B., Moreno V. Study of the modifications caused by cisplatin, transplatin, and Pd(II) and Pt(II) mepirizole derivatives on pBR322 DNA by atomic force microscopy. Int. J. Pharm. 245:2002;55-65
44. Phuchareon J., Tokuhisa T. Deregulated c-Fos/AP-1 modulates expression of the cyclin and the cdk gene in splenic B cells stimulated with lipopolysaccharide. Cancer Lett. 92:1995;203-208
45. Potapova O., Haghighi A., Bost F., Liu C., Birrer M.J., Gjerset R., Mercola D. The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J. Biol. Chem. 272:1997;14041-14044
46. Potapova O., Gorospe M., Bost F., Dean N.M., Gaarde W.A., Mercola D., Holbrook N.J. c-Jun N-terminal kinase is essential for growth of human T98G glioblastoma cells. J. Biol. Chem. 275:2000;24767-24775
47. Potapova O., Basu S., Mercola D., Holbrook N.J. Protective role for c-Jun in the cellular response to DNA damage. J. Biol. Chem. 276:2001;28546-28553
48. Richon V.M., Schulte N., Eastman A. Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells. Cancer Res. 47:1987;2056-2061
49. Rinehart-Kim J., Johnston M., Birrer M., Bos T. Alterations in the gene expression profile of MCF-7 breast tumor cells in response to c-Jun. Int. J. Cancer. 88:2000;180-190
50. Sancar A. Excision repair in mammalian cells. J. Biol. Chem. 270:1995;15915-15918. b
51. Scherer S.J., Maier S.M., Seifert M., Hanselmann R.G., Zang K.D., Muller-Hermelink H.K., Angel P., Welter C., Schartl M. p53 and c-Jun functionally synergize in the regulation of the DNA repair gene hMSH2 in response to UV. J. Biol. Chem. 275:2000;37469-37473
52. Schreiber M., Kolbus A., Piu F., Szabowski A., Mohle-Steinlein U., Tian J., Karin M., Angel P., Wagner E.F. Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev. 13:1999;607-619
53. Shaulian E., Karin M. AP-1 in cell proliferation and survival. Oncogene. 20:2001;2390-2400
54. Siddik Z.H. Cisplatin. mode of cytotoxic action and molecular basis of resistance Oncogene. 22:2003;7265-7279
55. Siddik Z.H., Mims B., Lozano G., Thai G. Independent pathways of p53 induction by cisplatin and X-rays in a cisplatin-resistant ovarian tumor cell line. Cancer Res. 58:1998;698-703
56. Smeal T., Binetruy B., Mercola D., Grover-Bardwick A., Heidecker G., Rapp U.R., Karin M. Oncoprotein-mediated signalling cascade stimulates c-Jun activity by phosphorylation of serines 63 and 73. Mol. Cell. Biol. 12:1992;3507-3513
57. Smith L.M., Birrer M.J. Use of transcription factors as agents and targets for drug development. Oncology (Huntingt.). 10:1996;1532-1538. 1541-1542
58. Smyth G.K., Speed T. Normalization of cDNA microarray data. Methods. 31:2003;265-273
59. Smyth G.K., Yang Y.H., Speed T. Statistical issues in cDNA microarray data analysis. Methods Mol. Biol. 224:2003;111-148
60. Steinmuller L., Thiel G. Regulation of gene transcription by a constitutively active mutant of activating transcription factor 2 (ATF2). Biol. Chem. 384:2003;667-672
61. Steinmuller L., Cibelli G., Moll J.R., Vinson C., Thiel G. Regulation and composition of activator protein 1 (AP-1) transcription factors controlling collagenase and c-Jun promoter activities. Biochem. J. 360:2001;599-607
62. Sturn A., Quackenbush J., Trajanoski Z. Genesis. cluster analysis of microarray data Bioinformatics. 18:2002;207-208
63. Takata M., Sasaki M.S., Sonoda E., Fukushima T., Morrison C., Albala J.S., Swagemakers S.M., Kanaar R., Thompson L.H., Takeda S. The Rad51 paralog Rad51B promotes homologous recombinational repair. Mol. Cell. Biol. 20:2000;6476-6482
64. van Dam H., Castellazzi M. Distinct roles of Jun. Fos and Jun: ATF dimers in oncogenesis Oncogene. 20:2001;2453-2464
65. van Dam H., Duyndam M., Rottier R., Bosch A., de Vries-Smits L., Herrlich P., Zantema A., Angel P., van der Eb A.J. Heterodimer formation of cJun and ATF-2 is responsible for induction of c-jun by the 243 amino acid adenovirus E1A protein. EMBO J. 12:1993;479-487
66. van Dam H., Wilhelm D., Herr I., Steffen A., Herrlich P., Angel P. ATF-2 is preferentially activated by stress-activated protein kinases to mediate c-jun induction in response to genotoxic agents. EMBO J. 14:1995;1798-1811
67. van Dam H., Huguier S., Kooistra K., Baguet J., Vial E., van der Eb A.J., Herrlich P., Angel P., Castellazzi M. Autocrine growth and anchorage independence. two complementing Jun- controlled genetic programs of cellular transformation Genes Dev. 12:1998;1227-1239
68. Vasilevskaya I.A., Rakitina T.V., O'Dwyer P.J. Geldanamycin and its 17-allylamino-17-demethoxy analogue antagonize the action of Cisplatin in human colon adenocarcinoma cells. differential caspase activation as a basis for interaction Cancer Res. 63:2003;3241-3246
69. Vial E., Perez S., Castellazzi M. Transcriptional control of SPARC by v-Jun and other members of the AP1 family of transcription factors. Oncogene. 19:2000;5020-5029
70. Vogt P.K. Jun, the oncoprotein. Oncogene. 20:2001;2365-2377
71. Wolfinger R.D., Gibson G., Wolfinger E.D., Bennett L., Hamadeh H., Bushel P., Afshari C., Paules R.S. Assessing gene significance from cDNA microarray expression data via mixed models. J. Comput. Biol. 8:2001;625-637
72. Yazgan O., Pfarr C.M. Regulation of two JunD isoforms by Jun N-terminal kinases. J. Biol. Chem. 277:2002;29710-29718
73. You S.N. Introduction of related indices in the evaluation of periodicals. Zhonghua Nei Ke Za Zhi. 42:2003;609-610
74. Zlatanova J., Yaneva J., Leuba S.H. Proteins that specifically recognize cisplatin-damaged DNA. a clue to anticancer activity of cisplatin FASEB J. 12:1998;791-799